Brief: Ascelia Pharma Meets Primary Endpoint In Orviglance Phase 3 Study

Ascelia Pharma AB

02/05/2024 12:22

May 2 (Reuters) - Ascelia Pharma AB  ACELP.ST :
    * SUCCESSFULLY MEETS PRIMARY ENDPOINT WITH STRONG HEADLINE
RESULTS
IN ORVIGLANCE PHASE 3 STUDY
    * LIVER IMAGING DRUG CANDIDATE, ORVIGLANCE®, SIGNIFICANTLY
IMPROVED VISUALIZATION OF FOCAL LIVER LESIONS
    * SUBMISSION OF NEW DRUG APPLICATION (NDA) FILE TO US FOOD
AND
DRUG ADMINISTRATION (FDA) IS EXPECTED BY MID-2025

Source text for Eikon:  ID:nMFNbvhzTg 
Further company coverage:  ACELP.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))